ENABLE

Full Clinical Trial Name

REal world experieNce with BRIUMVI® (ublituximAB-xiiy)  treated patients:  a Longitudinal rEgistry study (ENABLE)

Clinical Trial

  • Neurology

Phase

Phase
4

Patient Type

Adult
Doctor(s) running this study
Gary W. Clauser, MD
Location(s):
Call 610-402-9543
Search more clinical trials

Purpose

The purpose of this observational research study is to evaluate the safety, effectiveness, and to gain insight into the treatment experience of patients prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting by looking at recorded health facts.

Description

This is a phase 4 post-authorization observational study collecting data on the infusion treatment of BRIUMVI® with participants who have relapsing forms of Multiple Sclerosis. Participants that are prescribed the FDA approved BRIUMVI®, may enroll in this clinical study. Observational studies are carried out by researchers to identify and/or measure effects of medicines or treatment under real-life conditions. The researchers do this by looking at the information that is being collected by their doctor as part of their routine care. 

Eligibility

Inclusion Criteria
  1. Must be 18 years or older with relapsing form of Multiple Sclerosis.
  2. Confirmed Multiple Sclerosis diagnosis.
  3. Patients must NOT have received any BRUMVI infusion prior to enrollment of the study.

Learn more about the full clinical trial

Full description at clinicaltrials.gov

Doctor(s) running this study